The combination of recombinant rAd-p53 and adriamycin for management of primary drug resistance in c

• 作 者: 都昌胡
• 机 构: Guangzhou Instit Respir Dis Guangzhou Med Coll Guangzhou 510120,
• 出 处: China Medical Abstracts(Internal Medicine)
• 发表日期: 2006年04期
• 关键词: adriamycin squamous nude chemotherapy substitution alone suppressed loaded adeno

Objective To investigate the combination of wildtype p53 (wtp53) gene substitution and adriamycin (ADM) on the lung cancer in vivo. Methods The effect of combination of recombinant Adeno-wtp53 (rAdp53) and ADM on reversing primary drug resistance to ADM was studied for the nonsmall cell lung cancer (NSCLC) in a nude mice model developed by subcutaneously transplanting with the 16HBE lung cancer cell

Objective To investigate the combination of wildtype p53 (wtp53) gene substitution and adriamycin (ADM) on the lung cancer in vivo. Methods The effect of combination of recombinant Adeno-wtp53 (rAdp53) and ADM on reversing primary drug resistance to ADM was studied for the nonsmall cell lung cancer (NSCLC) in a nude mice model developed by subcutaneously transplanting with the 16HBE lung cancer cell